Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma

Table 3 Univariate and multivariable analyses of overall survival of hepatocellular carcinoma patients

	Univariate cox regression				Multivariate logistic regression
	HR	[0.025	0.975]	P	HR	[0.025	0.975]	P
Age, yr	1.020	1.000	1.030	0.010	1.02	1.00	1.03	0.01
Gender	1.570	1.030	2.390	0.030	1.42	0.89	2.26	0.14
HBsAg-positive	1.600	1.030	2.490	0.040	1.32	0.82	2.12	0.25
AFP	1.100	0.830	1.460	0.500
CEA	0.760	0.460	1.270	0.300
CA125	0.580	0.280	1.220	0.150
CA19-9	0.630	0.420	0.950	0.030	0.65	0.41	1.03	0.07
ALT, U/L	1.121	0.453	1.976	0.430
AST, U/L	1.342	0.876	2.014	0.540
FIB-4 score	1.012	0.547	1.743	0.720
Liver cirrhosis	1.112	0.563	1.956	0.550
Tumor size x	1.080	1.010	1.160	0.040	0.96	0.85	1.09	0.56
Tumor size y	1.090	1.020	1.170	0.010	1.17	1.02	1.33	0.02
Gray-scale echogenicity	0.830	0.670	1.020	0.080	0.77	0.60	0.99	0.04
Arterial phase enhancement	0.680	0.420	1.110	0.130
Portal phase enhancement	1.270	0.990	1.620	0.060	1.25	0.95	1.63	0.11
Portal phase Enhancement	1.130	0.810	1.580	0.460
Enhancing capsules	1.110	0.720	1.710	0.630
Satellite nodules	1.190	0.780	1.830	0.420
Unsmooth margins	0.720	0.520	0.990	0.040	0.79	0.56	1.13	0.19
Early reoccurrence	1.290	0.990	1.680	0.060	1.25	0.93	1.67	0.14
Retreatment after recurrence	0.710	0.540	1.160	0.300
DLR	3.240	2.670	3.930	< 0.005

HR: Hazard ratio; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA125: Carbohydrate antigen 125; CA19-9: Carbohydrate antigen 19-9; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FIB-4 score: Fibrosis-4 score; DLR: Deep learning-based radiomics.